JOHNSON & JOHNSON reported revenue of $25.31B for the period ended 2026-06-28, +6.6% year on year. Net income was $5.53B, a 21.9% net margin on a 100.0% gross margin. The largest revenue line is Med Tech at 35% of the total. Free cash flow for the period was $7.29B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $25.31B | +6.6% |
| Gross profit | $25.31B | — |
| Operating income | $6.75B | — |
| Net income | $5.53B | -0.1% |
| Gross margin | 100.0% | Net margin 21.9% |
| Revenue Q/Q | +5.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| Med Tech | $8.93B | 35.3% |
| Oncology | $7.41B | 29.3% |
| Immunology | $3.84B | 15.2% |
| Neuroscience | $2.34B | 9.2% |
| Pulmonary Hypertension | $1.14B | 4.5% |
| Cardiovascular Metabolism Other | $0.89B | 3.5% |
| Infectious Diseases | $0.76B | 3.0% |
| Item | Amount | % of revenue |
|---|---|---|
| SG&A | $6.43B | 25.4% |
| Tax & other | $1.21B | 4.8% |
| Item | Amount |
|---|---|
| Total assets | $201.06B |
| Total liabilities | $116.09B |
| Shareholders' equity | $84.97B |
| Equity / assets | 42.3% |
| Operating cash flow | $8.62B |
| Capital expenditure | $1.32B |
| Free cash flow | $7.29B |
| Cash conversion (OCF / net income) | 156% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
JCI ・ JPM ・ KVUE ・ KDP ・ KEY ・ KEYS ・ KMB ・ KIM ・ KMI ・ KKR ・ KLAC ・ KHC
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies